April 7, 2017
Takeda Pharmaceutical said on April 6 that it has completed the enrollment of over 20,000 children and adolescents in a global PIII trial for its live-attenuated tetravalent dengue vaccine candidate TAK-003. The Japanese drug titan is conducting the TIDES study,...read more